|
Experiment 1
|
Arthritis score
|
Paw volume
|
|---|
|
Treatment
|
Day 19
|
Day 28
|
Day 19
|
Day 28
|
|---|
|
AA/PBS
|
--
|
--
|
--
|
--
|
|
AA/PBS-liposomes
|
+23% ± 29.4%
|
+36% ± 56.5%
|
+ 2% ± 38.8%
|
+47% ± 62.3%
|
|
AA/DxM-P
|
-51% ± 17.8%
|
+ 4% ± 41.7%
|
-65% ± 14.0%
|
-13% ± 26.4%
|
|
AA/liposomal DxM-P
|
-95% ± 3.2%++ ##
|
-54% ± 28.7%
|
-92% ± 7.4%++ #
|
-73% ± 17.3% +
|
|
Experiment 2/3
|
Arthritis score
|
Paw volume
|
|
Treatment
|
Day 19
|
Day 29*
|
Day 19
|
Day 29*
|
|
AA/PBS
|
--
|
--
|
--
|
--
|
|
AA/PBS-liposomes
|
+15% ± 19.8%
| |
+23% ± 20.3%
| |
|
AA/DxM-P
|
-67% ± 16.4% + #
| |
-52% ± 21.8% + #
| |
|
AA/liposomal DxM-P
|
-90% ± 5.0%++ ##
| |
-87% ± 6.6.%++ ##
| |
|
AA/liposomal DxM-P 1× *
|
-48% ± 23.9%
|
-15% ± 29.6%
|
-63% ± 24.6%
|
-35% ± 22.6%
|
- Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with PBS-liposomes, free DxM-P (3 × 1 mg/kg; Days 14, 15 and 16), or liposomal DxM-P (3 × 1 mg/kg; Days 14, 15 and 16) compared to AA/PBS (Experiment 1 corresponds to the data in Figure 1). For comparison, the effects of treatment with single-dose liposomal DxM-P (1 × 1 mg/kg; Day 14; Experiment 3) are shown. * results from a separate subgroup of animals (named Experiment 3 for clarity) from the same arthritis study with similar disease severity on Days 19 and 20 as the other subgroup of animals (named Experiment 2).
- Data are expressed as means ± standard error of the mean.
- + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. PBS-liposomes.
